A Multicenter, Open-label Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Iberdomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 29 Nov 2017 Planned End Date changed from 14 May 2020 to 14 May 2022.
- 29 Nov 2017 Planned primary completion date changed from 16 Apr 2020 to 31 Mar 2018.
- 26 Apr 2017 Planned End Date changed from 14 Jun 2020 to 14 May 2020.